Literature DB >> 6168414

Protein clearances and selectivity determinations in childhood nephrosis: a reappraisal.

D Ellis, G J Buffone.   

Abstract

To critically evaluate the clinical utility of determining specific proteins in patients with extensive proteinuria, we used immunonephelometric methods to measure albumin, transferrin, IgG, and alpha 2-macroglobulin in serum and in 24-h urine specimens from 37 children with idiopathic nephrotic syndrome. Renal biopsy demonstrated minimal change disease (I) in 15, focal glomerulosclerosis (II) in 15, and membranoproliferative glomerulonephritis (III) in seven patients. A three-group nonparametric rank test and three-group discriminant function analysis of the protein excretion and clearances of the four proteins we measured revealed significant differences in the excretion of IgG and the clearance of alpha 2-macroglobulin among the three groups of patients (p less than 0.05). Only patients with III had low serum complement C3 concentrations. Patients with I or II were best discriminated by differences in the excretion of transferrin and IgG, the clearance of alpha 2-macroglobulin, and the selectivity index (the clearance ratio of IgG/transferrin). These data indicate that measurement of specific urinary proteins and selectivity determinations may be helpful in predicting the type of histopathology and the prognosis of nephrotic children who have normal complement concentrations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6168414

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  New selectivity index calculated using protein fraction as a substitute for the conventional selectivity index.

Authors:  Jun Nakamura; Katsuyuki Nagatoya; Naohiko Fujii; Aki Warada; Atsuyuki Tokuyama; Satoshi Masuyama; Sachio Kajimoto; Ryota Haga; Atsushi Yamauchi
Journal:  Clin Exp Nephrol       Date:  2019-06-06       Impact factor: 2.801

2.  Differentially expressed urinary biomarkers in children with idiopathic nephrotic syndrome.

Authors:  C P Suresh; Abhijeet Saha; Manpreet Kaur; Ritesh Kumar; N K Dubey; Trayambak Basak; Vinay Singh Tanwar; Gaurav Bhardwaj; Shantanu Sengupta; Vineeta Vijay Batra; Ashish Datt Upadhyay
Journal:  Clin Exp Nephrol       Date:  2015-09-09       Impact factor: 2.801

3.  Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Authors:  Melanie S Joy; Debbie S Gipson; Leslie Powell; Jacqueline MacHardy; J Charles Jennette; Suzanne Vento; Cynthia Pan; Virginia Savin; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Am J Kidney Dis       Date:  2009-11-22       Impact factor: 8.860

Review 4.  Focal segmental glomerulosclerosis.

Authors:  I Ichikawa; A Fogo
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

5.  In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.

Authors:  Melanie S Joy; Reginald F Frye; Thomas D Nolin; Brittney V Roberts; Mary K La; Jinzhao Wang; Kim L R Brouwer; Mary Anne Dooley; Ronald J Falk
Journal:  Pharmacotherapy       Date:  2013-09-06       Impact factor: 4.705

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.